Mangoceuticals, Inc. (MGRX)
NASDAQ: MGRX · Real-Time Price · USD
2.480
+0.040 (1.64%)
At close: Dec 20, 2024, 4:00 PM
2.400
-0.080 (-3.23%)
After-hours: Dec 20, 2024, 5:48 PM EST
Company Description
Mangoceuticals, Inc. develops, markets, and sells various men’s wellness products and services through a telemedicine platform in the United States.
It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name.
The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com.
Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program.
The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
Mangoceuticals, Inc.
| Country | United States |
| Founded | 2021 |
| IPO Date | Mar 21, 2023 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Jacob Cohen |
Contact Details
Address: 15110 North Dallas Parkway, Suite 600 Dallas, Texas 75248 United States | |
| Phone | 214 242 9619 |
| Website | mangoceuticals.com |
Stock Details
| Ticker Symbol | MGRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001938046 |
| CUSIP Number | 56270V106 |
| ISIN Number | US56270V1061 |
| Employer ID | 87-3841292 |
| SIC Code | 8090 |
Key Executives
| Name | Position |
|---|---|
| Jacob D. Cohen | Co-Founder, Chief Executive Officer and Chairman |
| Eugene M. Johnston | Chief Financial Officer |
| Amanda Elizabeth Hammer | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 19, 2024 | 8-K | Current Report |
| Dec 6, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Oct 31, 2024 | 8-K | Current Report |
| Oct 25, 2024 | 8-K | Current Report |
| Oct 22, 2024 | 8-K | Current Report |
| Oct 21, 2024 | 8-K | Current Report |
| Oct 11, 2024 | 8-K | Current Report |
| Oct 3, 2024 | 8-K | Current Report |